Toronto, Ontario--(Newsfile Corp. - June 20, 2016) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the
"Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today
confirms it is qualifying devices from multiple manufacturers with the aim to bring to market new Smartphone connected health and
cardiac monitoring technologies. CardioComm Solutions approved devices will be supported by the CardioComm Solutions' SMART
Monitoring ECG reading and GEMS™ WIN for use by consumers, physicians and hospital systems.
CardioComm Solutions has pre-qualified several devices of interest and expects pending sales and marketing agreements with
manufacturers to be executed in 2016. When testing and integration is completed, the Company intends to apply for and secure Class
II medical device clearances for sales of the devices in the USA and Canada under the HeartCheck™ brand. The Company will hold
exclusive rights for the sale of the HeartCheck™ branded devices in North America. In turn, the integrated devices would be
permitted to be distributed through the original devices' manufacturer's distribution networks under their own OEM agreements and
brands in overseas markets while promoting connectivity to the CardioComm Solutions' ECG management software and ECG reading
services. Multiple revenue streams for CardioComm Solutions will be created through direct sales from HeartCheck™ branded devices,
a percentage of device sales from device manufacturer OEM sales overseas, and recurrent revenue generated through software
licensing or fee-for-service use of the SMART Monitoring ECG reading service from all devices sold.
While large wellness product companies, continue to try and out-compete each other by adding more and more built in sensor
technologies to monitor wellness, sleep and activity, and consumers look for more credible health monitoring, there are no clear
signs that these companies will seek medical device clearances for their devices. The CardioComm Solutions announcement signals
that this may soon change.
CardioComm Solutions' strategy is to focus on its established medical software engineering solutions and leverage its 17 years
of medical device integration experience to enable new Medical-Wellness products to be cleared as Class II medical devices. The
anticipated new HeartCheck™ devices will cover the wrist band, Smartphone case, chest strap, wearable ECG patches and cards
utilizing Wi-Fi, Bluetooth, GSM or USB technologies to transfer data to Smartphones, computers or the Cloud where data can be
reviewed and shared with healthcare professionals as needed.
The device manufacturer partnerships will provide CardioComm Solutions with access to a supply of new and already developed
hardware technologies without the associated high hardware development costs. Partnering device companies in turn benefit from
immediate access to CardioComm Solutions' market-ready, physician proven ECG software technologies. Adding ECG and cardiac rhythm
recording/monitoring, in addition to the array of established common-place wellness sensor technologies, would provide a
differentiating and competitive edge for CardioComm Solutions and its device partners. Combined, the companies plan to bring to
market novel devices with shorter product development cycle times, simplified medical device clearance applications and a lower
cost of goods to the end user when compared to products from the likes of Samsung, Apple, Fitbit, AliveCor and Microsoft.
CardioComm Solutions' goal is to establish a new class of Medical-Wellness and medical-grade health monitoring devices that will
make it easier for consumers, and their physicians, to understand changes in their health patterns and manage serious health
conditions.
CardioComm Solutions will be providing further updates as device partnership agreements are executed. CardioComm Solutions'
technologies hold clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), Australia (TGA), the
USA (FDA), China (CFDA) and Canada (Health Canada). To learn more about the CardioComm Solutions' products please see the Company's
websites www.theheartcheck.com and www.cardiocommsolutions.com or contact the Company at sales@cardiocommsolutions.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an
external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in
Toronto, Ontario, Canada.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial
condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm
Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on
information currently available to management. By their nature, forward-looking statements and forward-looking information involve
risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many
factors that could cause actual results and developments to differ materially from those expressed or implied by these
forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking
information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information
contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
